ZIMLAB2024-04-012024-06-30 ZIMLAB2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member ZIMLAB2024-06-30 ZIMLAB2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 541400 ZIMLAB NA Zim Laboratories Limited Equity 2024-04-01 2025-03-31 2024-08-03 2024-07-27 INR Lakhs First quarter 15:00:00 18:15:00 2024-08-03 2024-08-03 Not applicable Single segment Pharmaceutical Industry 2024-04-01 2024-06-30 Unaudited Standalone 820041000.00 9803000.00 829844000.00 310093000.00 26574000.00 31437000.00 134805000.00 28575000.00 49160000.00 238358000.00 819002000.00 10842000.00 0.00 10842000.00 2100000.00 1152000.00 3252000.00 0.00 7590000.00 0.00 0.00 0.00 0.00 7590000.00 -955000.00 6635000.00 6635000.00 0.00 487258000.00 10 0.16 0.16 0.00 0.00 0.16 0.16 0.00 0.01 0.01 Notes : 1) The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 03 August 2024. There are no qualifications in the limited review report issued for the quarter ended 30 June 2024. 2) These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India (SEBI). 3) The figures for the quarter ended 31 March 2024 are the balancing figures between the audited figures for the year ended 31 March 2024 and the unaudited year to date figures upto 31 December 2023, on which auditors had performed a limited review. 4) The Company is principally engaged in a single business segment which is pharmaceuticals . 5) During the current quarter, the Nomination and Remuneration Committee of the Company on 13 April 2024 had granted 687,257 stock options to eligible employees of the Company and its subsidiary pursuant to the scheme, 'ZIM Laboratories Employee Stock Option Scheme, 2023”. Place: Nagpur Anwar S. Daud Date: 03 August 2024 Other Expenses 238358000.00 Measurements of defined employee benefit plans -1347000.00 -1347000.00 -392000.00 0.00